arrow
J

Jeffrey Tyner

Oregon Health and Science University
H指数:70
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia

BRAF突变在急性髓系白血病中的预后和治疗意义

Leukemia
IF13.4
2026-06-150
OAAI
Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets

整合蛋白质组学和代谢组学分析急性髓系白血病以识别分子亚型及相关治疗靶点

2026-06-120
OA
The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor

芳基烃受体与单核细胞白血病和可被AHR抑制剂逆转的固有免疫抵抗相关。

2025-12-090
OA
Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

新型BCL-XL降解剂DT2216在髓系增殖性肿瘤后继发性急性髓系白血病预临床模型中的疗效

BLOOD
IF23.1
2024-11-050
PRE
PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

PTPN11基因突变与接受表观遗传药物(包括低甲基化剂和Venetoclax)治疗的急性髓系白血病患者生存期缩短相关。

BLOOD
IF23.1
2024-11-050
PRE
Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents plus Venetoclax in Newly Diagnosed AML

免疫表型标志物CD7和CD56可改善一线低甲基化药物联合Venetoclax在初诊AML中的风险分层

BLOOD
IF23.1
2024-11-050
PRE
Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

I期临床试验:评估Entrectinib与ASTX727新型联合疗法在TP53突变复发/难治性急性髓系白血病患者中的疗效

BLOOD
IF23.1
2024-11-050
PRE
NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

NCAM1 (CD56) 作为新诊断急性髓系白血病对标准强化诱导治疗的应答预测指标

BLOOD
IF23.1
2024-11-050
PRE
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia

多组学分析确定非裔美国急性髓系白血病患者的生存预测因子

2024-10-041
OAAI
Proteogenomic and metabolomic characterization of acute myeloid leukemia
2024-03-220
PRE
Mapping the proteogenomic landscape enables prediction of drug response in acute leukemia
2024-01-013
OAAI